EHA 2026: Caribou Biosciences CEO Rachel Haurwitz shares an EHA update on her company's CD19 and BCMA allogeneic CAR-T programs
She shares a data update for both, which she believes are as strong as autologous CAR-T, and discusses recent FDA feedback Caribou has received from FDA on the pivotal trial design for the CD19 program in 2L LBCL.









.png)